ReviewNature reviews. Nephrology2018
The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease.
Review in Nature reviews. Nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06645535 (The Role and Mechanism of Gut Microbiota and Metabolites in Heart Failure With Preserved Ejection Fraction), which is not on this map. Cited by 447 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Role and Mechanism of Gut Microbiota and Metabolites in Heart Failure With Preserved Ejection Fraction
Who cites it
447 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Gut microbiota changes in patients with hypertension: A systematic review and meta-analysis.Journal of clinical hypertension (Greenwich, Conn.) · 2023Pooled it
- Yi-Shen-Hua-Shi regulates intestinal microbiota dysbiosis and protects against proteinuria in patients with chronic kidney disease: a randomized controlled study.Pharmaceutical biology · 2024Trial
- Determinants of enteric hyperoxaluria in the SAMP1/YitFc mouse model of spontaneous ileitis.Gut microbes · 2026Article
- Targeting the gut-kidney axis to improve kidney transplantation prognosis: from mechanisms to clinical intervention strategies.Renal failure · 2026Review
- Gut dysbiosis, blood pressure regulation, and cardiometabolic risk in polyendocrine metabolic ovarian syndrome (PMOS).Reviews in endocrine & metabolic disorders · 2026Review
- Targeting Interleukin-6 for Treatment of CKD and Cardiovascular Disease.Kidney international reports · 2026Review
- Gut Microbiota and Their Metabolites in Acute Kidney Injury: Classification, Mechanisms, and Therapeutic Potential.Metabolites · 2026Review
- Long-Term or Recurrent Antibiotic Use During Childhood or Adolescence and the Risk of Kidney Cancer: A Cohort Study.Cancer medicine · 2026Article
- Review
- Risk factor obesity: treatment standard.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Review
- Article
- The gut microbiome and allograft outcomes: implications for heart transplantation.The Journal of clinical investigation · 2026Review
- Vegetarian diet is associated with a lower risk of chronic kidney disease in a population-based study.Scientific reports · 2026Article
- A new paradigm in Parkinson's disease: kidney-origin α-synuclein pathology driven by PKC signaling and aurothioglucose.Inflammopharmacology · 2026Review
- Proanthocyanidins Attenuate Cisplatin-Induced Acute Kidney Injury and are Associated With Reshaping Gut Microbiota and Restoring Redox Homeostasis.Molecular nutrition & food research · 2026Article
- Comparative genomics of Bifidobacterium crudilactis NASR_001 - unveiling the tapestry of a putative probiotic.Gut pathogens · 2026Article
- Depressive symptoms in chronic kidney disease: the hidden role of uremic toxins.BMJ mental health · 2026Article
- From Parallel Programming to Bidirectional Crosstalk: The Brain-Kidney Axis in Cardiovascular-Kidney-Metabolic Syndrome.Antioxidants (Basel, Switzerland) · 2026Review
- Life-Course Programming of Kidney Disease: Roles of Gut Microbiota Dysbiosis and Oxidative Stress.Antioxidants (Basel, Switzerland) · 2026Review
- Early diabetes-like phenotypes in germ-free mice induced by gut microbiota from patients with type 2 diabetes.Animal models and experimental medicine · 2026Article
387 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Crosstalk between the gut microbiota and the host has attracted considerable attention owing to its involvement in diverse diseases. Chronic kidney disease (CKD) is commonly associated with hypertension and is characterized by immune dysregulation, metabolic disorder and sympathetic activation, which are all linked to gut dysbiosis and altered host-microbiota crosstalk. In this Review, we discuss the complex interplay between the brain, the gut, the microbiota and the kidney in CKD and hypertension and explain our brain-gut-kidney axis hypothesis for the pathogenesis of these diseases. Consideration of the role of the brain-gut-kidney axis in the maintenance of normal homeostasis and of dysregulation of this axis in CKD and hypertension could lead to the identification of novel therapeutic targets. In addition, the discovery of unique microbial communities and their associated metabolites and the elucidation of brain-gut-kidney signalling are likely to fill fundamental knowledge gaps leading to innovative research, clinical trials and treatments for CKD and hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.